MedTrace Logo

Pilot Study Using Neoadj Chemo-Rad & EGFR-tyrosine Kinase Inhibitor for Potentially Resectable Pancreatic Cancer

NCT00243854 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2014-03-18

No results posted yet for this study

Summary

To determine the feasibility and toxicity of neoadjuvant hypofractioned radiotherapy concurrently with weekly gemcitabine and an EGFR tyrosine-kinase inhibitor (OSI-774, Tarceva) in the treatment of patients with resectable pancreatic cancer.

Conditions

Interventions

DRUG

Tarceva

Tarceva: 100mg/day x 2 weeks (Days 1-14) +

Sponsors & Collaborators

  • Genentech, Inc.

    collaborator INDUSTRY

  • Indiana University School of Medicine

    lead OTHER

Principal Investigators

  • Higinia Cardenes, M.D., PhD · Indiana University

  • Gabriela Chiorean, M.D. · Indiana University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-11-30
Primary Completion
2010-08-31
Completion
2011-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00243854 on ClinicalTrials.gov